During our live Management Briefing with Craig Mull, interim CEO, and Brian Jacobs, CFO of Cipher Pharmaceuticals, Inc. (OTC:CPHRF) (CPH.TO), we were provided with detailed insights into their asset purchase agreement with ParaPRO LLC ("ParaPRO") and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total consideration of US$89.5 million.
Acquisition Details and Strategic Fit
